Literature DB >> 1979745

Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection.

P Putkonen1, R Thorstensson, J Albert, K Hild, E Norrby, P Biberfeld, G Biberfeld.   

Abstract

Simian immunodeficiency virus (SIV) infection in cynomolgus macaques leads to severe immunodeficiency with a fatal outcome. In contrast, HIV-2 infects these primates without apparently causing any immunological abnormalities. In this study three cynomolgus monkeys were experimentally infected with HIV-2 strain SBL-K135 and 168 days later challenged with 10-100 animal infectious doses of the closely related SIV strain SM to study protective immunity. At the time of SIV challenge the HIV-2-infected monkeys had neutralizing antibodies against HIV-2, but virus could no longer be recovered from their peripheral blood mononuclear cells (PBMCs) and no clinical symptoms or decrease in CD4+ lymphocytes were observed. Follow-up for 9 months after challenge with SIV showed that the HIV-2-infected monkeys were protected against SIV-induced immunodeficiency (no decrease of CD4+ lymphocytes) and lymphadenopathy. However, they were not resistant to SIV infection since virus could be recovered from their PBMCs and they developed anamnestic antibody responses. Four naive control monkeys which were inoculated with the same dose of SIV became persistently infected and developed a decrease of the absolute numbers of CD4+ cells and showed a marked lymphadenopathy. Two out of four control animals died 58-265 days postinfection with an immunosuppressive disease. Immunohistochemical examination showed abundant viral antigen in lymph-node biopsies from the SIV-infected control monkeys but absence of SIV or HIV-2 antigens in the biopsies from the three HIV-2-preinfected and SIV-superinfected monkeys. The present study demonstrates possibilities for induction of immunity against immunodeficiency induced by a primate lentivirus, a concept with application also to HIV infection and AIDS in man.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979745     DOI: 10.1097/00002030-199008000-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

Review 1.  Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm?

Authors:  W C Koff; A M Schultz
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

2.  Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors:  E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

3.  Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.

Authors:  R Shibata; C Siemon; M W Cho; L O Arthur; S M Nigida; T Matthews; L A Sawyer; A Schultz; K K Murthy; Z Israel; A Javadian; P Frost; R C Kennedy; H C Lane; M A Martin
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Toll-like Interleukin -1 Receptor Regulator (TILRR) Protein, a Major Modulator of Inflammation, is Expressed in Normal Human and Macaque Tissues and PBMCs.

Authors:  Francis A Plummer; Mohammad Abul Kashem; Lin Li; Xin-Yong Yuan; Ma Luo
Journal:  J Inflamm Res       Date:  2022-05-12

5.  Serological, biological, and molecular characterization of New Zealand white rabbits infected by intraperitoneal inoculation with cell-free human immunodeficiency virus.

Authors:  S Reina; P Markham; E Gard; F Rayed; M Reitz; R C Gallo; O E Varnier
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

Review 6.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

7.  The induction of in vivo superinfection and recombination using feline immunodeficiency virus as the model.

Authors:  M T Kyaw-Tanner; W K Greene; H S Park; W F Robinson
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  Transcomplementation of simian immunodeficiency virus Rev with human T-cell leukemia virus type I Rex.

Authors:  K J Krohn; K Hakkarainen; E Aavik; S Dewhurst; R Sadaie; J I Mullins
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.

Authors:  M Mamounas; D J Looney; R Talbott; F Wong-Staal
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.

Authors:  K H Siebelink; E Tijhaar; R C Huisman; W Huisman; A de Ronde; I H Darby; M J Francis; G F Rimmelzwaan; A D Osterhaus
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.